American Society of Hematology (ASH) presented fresh abstracts from a strong portfolio and pipeline of cutting-edge treatment platforms for cancer and blood diseases, underscoring the significance of our audacious science in research. Delveinsight has provided a summary of some of the key abstracts and their results for follicular lymphoma (FL).

The key abstracts have been summarized in the table below:

Drug regimen

Abstract Title

Trial ID

Company

Class

ORR

CR

Odronextamab

Odronextamab in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Grade 1â3a: Results from a Prespecified Analysis of the Pivotal Phase II Study ELM-2

NCT03888105

(ELM-2)

Regeneron Pharmaceuticals

Bispecific antibody

81%

75%

Zandelisib1

(ME-401)

Efficacy and Safety of Single-Agent Zandelisib Administered By Intermittent Dosing in Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Final Results of the Tidal Phase 2 Study

NCT03768505

(TIDAL)

MEI Pharma

phosphatidylinositol 3-kinase (PI3K) delta inhibitor

85%

42%

Polatuzumab vedotin + Lenalidomide + Obinutuzumab

A Phase Ib/II Study of Polatuzumab Vedotin Plus Obinutuzumab and Lenalidomide in Patients with Relapsed/Refractory Follicular Lymphoma: Final Analysis and Progression-Free Survival Update

NCT02600897

Hoffmann-La Roche

Antibody Drug Conjugate

91%

72%

Mosunetuzumab2

Subcutaneous Mosunetuzumab Is Active with a Manageable Safety Profile in Patients (pts) with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphomas (B-NHLs): Updated Results from a Phase I/II Study

NCT02500407

(GO29781)

Roche

Bispecific antibody

77.8%

60%

Iberdomide + Obinutuzumab3

Iberdomide (CC-220) Monotherapy or in Combination with an Anti-CD20 Monoclonal Antibody As Effective Therapy in Patients with Relapsed/Refractory Lymphoma: Early Results from a Phase 1/2 Study

NCT04464798

BMS

Immunomodulatory imide drug (IMiDs)

69%

39%

Notes:

1. MEI Pharma and Kyowa Kirin announced discontinuing Zandelisib development outside of Japan for B-cell malignancies. Moreover, Kyowa Kirin is continuing the ongoing clinical trials, including the Phase II MIRAGE study evaluating Japanese patients with relapsed or refractory indolent B-cell non-Hodgkin lymphomas and will explore the potential for submission to Japanese health authorities based on data from the MIRAGE and TIDAL clinical trials.

2. Lunsumio (mosunetuzumab) is already approved by European Commission in June 2022 for the treatment of people with R/R Follicular Lymphoma who have received at least two prior systemic therapies. Additionally, it was the first and only fixed-duration bi-specific antibody to be approved in Europe for lymphoma. Moreover, Lunsumio is under Priority Review with the FDA, with a decision expected by 29 December 2022.

3. Novel CELMoD (Cereblon E3 ligase modulators) is being evaluated for the treatment of R/R Follicular Lymphoma.